Form 4: Steve Elms of Marker Therapeutics Acquires Additional Common Stock
SEC Form 4
Director Steve Elms reports acquisition of Marker Therapeutics common stock via a Securities Purchase Agreement.
Summary
- On December 23, 2024, Steve Elms, a director of Marker Therapeutics, acquired 11,085 shares of common stock at a price of $3.2 per share.
- This transaction was made pursuant to a Securities Purchase Agreement dated December 19, 2024.
- Following the reported transaction, Mr. Elms directly owns 2,968 shares and may be deemed to indirectly own 325,370 shares through Aisling Capital IV, LP.
- The reported securities are directly owned by Aisling Capital IV, LP ('Aisling'), and which may be deemed to be beneficially owned by Aisling Capital Partners IV, LP ('Aisling GP'), as general partner of Aisling, Aisling Capital Partners IV LLC ('Aisling Partners'), as general partner of Aisling GP, and each of the individual managing members and partners (collectively, the 'Managers') of Aisling GP and Aisling Partners.
- The Managers of Aisling Partners are Dr. Andrew Schiff and Steve Elms, who have shared voting and dispositive power over the shares.
- Mr. Elms disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It reflects a routine transaction by a company director. The purchase could be seen as a positive signal, but the disclaimer of beneficial ownership tempers the enthusiasm.
Positives
- Director's purchase of shares may signal confidence in the company's future prospects.
Management Comments
- Mr. Elms disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein, and the inclusion of these securities herein shall not be deemed an admission of beneficial ownership for purposes of Section 16 or for any other purpose.
Industry Context
Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to the market.
Stakeholder Impact
- The transaction could have a minor positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 01/26/2023 | Issuer effected a 1-for-10 reverse stock split of its common stock |
| 12/19/2024 | Date of the Securities Purchase Agreement |
| 12/23/2024 | Date of the transaction where Steve Elms acquired shares |
| 12/26/2024 | Date of the signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.